INTRODUCTION
Throughout the world, health practices are moving towards a more preventive approach,
showing attitudes that value healthier lifestyles and behaviors based on disease prevention.
In this context, it is also recognized that men and women seek strategies to reduce
the visible signs of aging1.
Following the example of North America, which currently ranks first, considering the
total number of surgical and non-surgical cosmetic and aesthetic procedures performed2. Brazil ranks second, being the first only when considering surgical procedures1,2.
However, in recent years, emphasis has been placed on minimally invasive aesthetic
procedures3. This trend culminated in the use of a variety of non-incisional methods to combat
the effects of aging, with the increased use of soft tissues in infiltrative facial
implants being the most popular4.
Currently, there are a large number of fillers available for this purpose, each with
its chemical composition, specific indications, and effectiveness5. This wide range of available materials requires aesthetic specialists and plastic
surgeons to choose the appropriate filler for each aesthetic complaint of their patients5,6.
The ideal filler applied to treat signs of aging or to increase soft tissue should
provide good cosmetic results and have a long-term effect. It must also be safe, biocompatible,
and stable at the implantation site, with low-risk, non-migratory complications6.
According to Lemperle et al., In 20067, all injectable dermal fillers can cause complications. Late side effects can be
divided into those caused by insufficient training or technical errors during the
injection, and those caused by immune reactions (allergic and non-allergic) to the
injected substance. Granuloma formations are rare events that result from type IV
hypersensitivity reaction to a foreign body. They usually occur over months to years
after the injection3.
Acute complications include those associated with the technique used during application
and are mostly local. However, due to a chronic inflammatory reaction, they may appear
years after infiltration, with the possibility of remission-reactivation episodes2,4.
The histological reaction is always similar, and the trigger for this sudden stimulation
of macrophages may be a systemic infection of the patient. Dermal fillers such as
silicone, bovine collagen, ArtecollTM (Hafod B.V, Rotterdam, The Netherlands), and RestylaneTM8 (Q-Med AB, Stockholm, Sweden) have been used worldwide.
Bovine collagen (ZydermTM, ZyplastaTM, McGhan Medical Corporation 3M, USA) was introduced between 1981 and 1983, becoming
the standard for injectables9. ArtecollTM (Canderm Pharma Inc., Canada) was distributed between 1994 and 2006, and RestylaneTM (Q-Med AB, Stockholm, Sweden) began its triumphal advance in 19978. Since then, a variety of materials have been introduced, such as RadiesseTM (Merz, Brazil), which is approved for facial bone augmentation and has been used
off-label since 2003 for the treatment of wrinkles10; and SculptraTM (Aventis, USA), which is approved for facial lipodystrophy of the human immunodeficiency
virus, but has been used to treat wrinkles since 2005. The Food and Drug Administration
(FDA - USA) approved RestylaneTM in 2003, HylaformTM (Genzy me Biosurgery, USA) in 2004, CaptiqueTM in 2005 and JuvedermemTM 2006 (both from Allergan, USA) for the treatment of facial wrinkles9.
The polymethylmethacrylate (PMMA) molecule does not have any animal component in its
structure, which makes this molecule a biocompatible material and also provides stability
even decades after the initial implantation. Its commercial applications are PMMA
microspheres suspended in bovine collagen2.
In the context of the indications of the PMMA compound, the filling of grooves, deep
wrinkles, scars, dermal defects, soft and bone tissues stands out6. It is also used in restorative procedures for volumetric facial and body correction
of lipodystrophy syndrome, a result of the use of antiretrovirals in patients with
the human immunodeficiency virus11.
Fat embolism syndrome (FES) is a poorly defined clinical entity that arises from systemic
manifestations of fat embolism within the microcirculation. Embolized fat in the capillary
beds causes direct tissue damage, in addition to inducing a systemic inflammatory
response, which produces pulmonary, cutaneous, neurological, and retinal symptoms.
It occurs more frequently after orthopedic trauma, as well as in patients with many
clinical conditions, including liposuction, bone marrow transplantation, pancreatitis,
however, as observed in the present study, rarely in bioplasty procedures using PMMA12.
OBJECTIVE
The present study aimed to carry out a systematic review of the literature in order
to highlight the clinical studies that included FES in patients undergoing PMMA infiltration
in bioplasty.
METHODS
Search strategies and eligibility criteria
A search of the PubMed/MEDLINE and LILACS / BVS databases was performed, including
articles that addressed the topic “fat embolism syndrome secondary to the use of PMMA
in bioplasty.”
We included studies in humans, older than 18 years (adults), whose publication in
English was between January 1, 2000, and January 8, 2019, and the text published with
full access reported on FES after bioplasty with use. PMMA intervention.
Review articles (meta-analyzes an/or systematics), letters to the editor, case reports,
and experimental studies in which the complication after using PMMA did not include
FES were not added.
After the response of the electronic databases, a manual search of relevant articles
was carried out, since the sample was not adequate. In this way, the search date was
extended from January 1970 to January 2019.
The following search terms were included in English: “fat embolism syndrome,” “polymethylmethacrylate,”
and “fat embolism syndrome.” In Portuguese: “PMMA,” “polimetilmetacrilato,” “síndrome embolia gordurosa,”
“embolia lipídica.” In Spanish: “PMMA,” “polimetilmetacrilato,” “embolia grasa,” “embolia lipídica.” As protocols, the recommendations of the Preferred reporting elements for systematic reviews and meta-analyzes were followed.
Data extraction
Research data, after extraction, was included, and the authors of this article reviewed
controversies. Information such as: authors, year of publication, and country of origin
was reviewed to identify and exclude duplicate publications from the same cohort.
The extracted data included the total number of patients and injuries, age, sex, and
occurrence.
RESULTS
In the PubMed/MEDLINE electronic search, 20 research article references were found.
After reading the titles, 18 references were excluded, leaving two references. When
read in full, two studies were excluded as they did not include bioplasty and the
use of PMMA. The exclusion of these articles was based on the inclusion and exclusion
criteria described above.
In the LILACS / VHL database, 59 references to research articles were found (subject
index). After reading the titles, 50 references were excluded, leaving nine references.
When reading in their entirety, three studies that did not contemplate bioplasty and
the use of PMMA were excluded, and the remaining six were also excluded because they
are liposuction related studies that do not consider the use of PMMA. The exclusion
of these articles was based on the inclusion and exclusion criteria described above.
In this way, a manual search was performed in the three languages (English, Portuguese,
and Spanish), and the search date was extended from January 1970 to January 8, 2019.
As a result, only one article was available for a complete reading. (Spanish language).
The selection criteria are described in Figure 1.
Figure 1 - Flowchart of the process of searching for articles and including inclusion, prepared
according to PRISMA.
Figure 1 - Flowchart of the process of searching for articles and including inclusion, prepared
according to PRISMA.
Chart 1 describes the only study selected, by manual search, for this article, in which it
presents the authors, the country of origin of the research, the main objectives and
the main characteristics of the study.
Chart 1 - Included studies: country of origin, methods and objectives and characteristics of
the study.
Author/year |
Country of Origin |
Methods and Objectives |
Study characteristics |
Salgado and Olvera, in 200813.
|
México |
Presentation of clinical case and outcomes. |
Clinical case report with outcomes after FES in a post-procedure patient with PMMA
infiltration
|
Chart 1 - Included studies: country of origin, methods and objectives and characteristics of
the study.
DISCUSSION
The bibliographic search resulted in a single article, according to the descriptors,
and the inclusion and exclusion requirements. Unfortunately, there is no significant
number of articles that address FES in PMMA infiltration. Most of the available reports
come from liposuction and correlate with bone trauma when PMMA use is mentioned.
The subject of the only report was a 26-year-old woman who started the condition 24
hours after PMMA injection into the bilateral gluteal region at a cosmetic clinic.
The patient presented fever, anxiety, diaphoresis, headache, dizziness, drowsiness,
and dysarthria13.
On physical examination at admission, blood pressure of 110/70mmHg was presented,
heart rate of 113 beats per minute, respiratory rate of 21 respiratory incursions
per minute, with supplemental support of oxygen by mask and nebulizer; body temperature
of 38.4° C, with Glasgow of 12. She was aware13.
Pelvic tomography revealed abundant, diffuse, non-encapsulated material between the
skin and the gluteus maximus. Her management was in the Intensive Care Unit, with
general support, mechanical ventilation in the volume control in assisted mode. Broad-spectrum
antibiotics and anticoagulation with low molecular weight heparin were also prescribed13.
The patient developed pneumonia, systemic inflammatory response syndrome, and cerebral
edema. Due to prolonged intubation and inadequate management of secretions, it was
necessary to perform a tracheostomy. She had a prolonged clinical evolution; however,
satisfactory, allowing her to remain without mechanical ventilation support. The infectious
respiratory focus was controlled, and the patient evolved with hemodynamic stability.
The patient was discharged after three weeks of hospitalization. In this case report,
massive PMMA infiltration destroyed adipose tissue, which, together with the microspheres
of this product, provoked fat embolism in the patient13.
The case presented by Salgado and Olvera in 200813 was of non-medical professionals who performed the procedure. This type of practice
has generated a public health problem, since most of the time, the subjects do not
have medical training, and there are no reliable statistics on the incidence or prevalence
of patient complications concerning the substances used. FES was first described in
1862, by Zenker, who visualized fat cells in the pulmonary circulation of a polytraumatized
individual after performing a biopsy14. The term FES is a severe consequence of fatty emboli that causes a distinct pattern
of symptoms and clinical signs15.
The typical clinical manifestation is the triad of acute respiratory failure, thrombocytopenia,
and neurological dysfunction15. No definitive diagnostic criteria or tests have been developed, which makes the
diagnosis of FES more difficult. It usually occurs within 48 hours after the trauma
or during surgical procedures in most patients12.
There are two main theories for the genesis of fat embolism; they are the mechanical
theory and the biochemical theory. The first suggests that the obstruction of the
systemic vasculature by fat embolism results from the direct release of the bone marrow
into the venous system after the trauma. High intramedullary pressure after trauma
causes the release of fat through open venous sinusoid. This embolized fat favors
the obstruction of the capillary beds12.
The second theory proposes that the inflammatory response to trauma causes the release
of free fatty acids from the bone marrow into the venous system. Elevations in free
fatty acids and inflammatory mediators damage the capillary beds. Elevated levels
of free fatty acids have been correlated with hypoxemia and the induction of pulmonary
inflammation12.
Regarding the therapeutic approach, there is no specific treatment for FES. The procedures
are based on clinical support measures, hemodynamic stabilization, volume replacement,
nutrition and oxygen therapy or mechanical ventilation with alveolar recruitment in
more severe cases14. There is insufficient data to support the initiation of steroid therapy, once FES
is established. The proposed mechanism of action is generally an anti-inflammatory
agent that reduces perivascular hemorrhage and edema. An experimental study did not
show a beneficial effect and there were no prospective, randomized, and controlled
clinical studies that demonstrated a significant benefit with its use15.
CONCLUSION
In the current aesthetic situation, there is a significant increase in minimally invasive
techniques that favor non-incisional methods, such as the implantation of PMMA, to
minimize the effects of aging and correct body defects. It is known that in order
to prevent or treat disorders, such as FES with dermal implants, it is essential to
know their composition, the physiological reactions of the tissue, the time of absorption,
and persistence. There is an urgent need for more studies targeting PMMA in cosmetic
procedures, their risks, and clinical cases that identify FES and other potentially
fatal postoperative problems for the patient.
COLLABORATIONS
CGAO
|
Analysis and/or data interpretation, Conception and design study, Conceptualization,
Data Curation, Final manuscript approval, Formal Analysis, Investigation, Methodology,
Project Administration, Resources, Supervision, Validation, Visualization, Writing
- Original Draft Preparation, Writing - Review & Editing
|
FRS
|
Analysis and/or data interpretation, Conceptualization, Final manuscript approval,
Investigation, Resources, Supervision, Validation, Visualization
|
FAAF
|
Conceptualization, Data Curation, Final manuscript approval, Supervision, Visualization,
Writing - Original Draft Preparation
|
RZDF
|
Final manuscript approval, Data Curation, Conceptualization, Writing - Original Draft
Preparation, Supervision, Visualization.
|
REFERENCES
1. Chacur R, Menezes HS, Chacur NMBS, Alves DD, Mafaldo RC, Gomes LD, et al. Replacement
of gluteal implants by polymethylmethacrylate filler: case report. Case Reports Plast
Surg Hand Surg. 2019 Jan;6(1):20-4.
2. Souza TAB, Colomé LM, Bender EA, Lemperle G. Brazilian consensus recommendation on
the use of polymethylmethacrylate filler in facial and corporal aesthetics. Aesthetic
Plast Surg. 2018 Oct;42(5):1244-51.
3. Vedamurthy M. Beware what you inject: complications of injectables - dermal fillers.
J Cutan Aesthet Surg. 2018 Apr/Jun;11(2):60-6.
4. Buck II DW, Alam M, Kim JYS. Injectable fillers for facial rejuvenation: a review.
J Plast Reconstr Aesthet Surg. 2009 Jan;62(1):11-8.
5. Parada MB, Cazerta C, Afonso JPJM, Nascimento DIS. Overview and management of fillers
complications. Surg Cosmet Dermatol. 2016;8(4):342-51.
6. Vargas AF, Amorim NG, Pitanguy I. Late complications of permanent fillers. Rev Bras
Cir Plást. 2009;24(1):71-81.
7. Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications.
Plast Reconstr Surg. 2006 Oct;118(3 Suppl 1):92S-107S.
8. Pollack SV. Some new injectable dermal filler materials: Hylaform, Restylane, and
Artecoll. J Cutan Med Surg. 1999 Dec;(3 Suppl 4):S27-35.
9. Johl SS, Burgett RA. Dermal filler agents: a practical review. Curr Opin Ophthalmol.
2006 Oct;17(5):471-9.
10. Viscusi KS, Hanke CW. Soft tissue augmentation. In: Baran R, Maibach HI, eds. Textbook
of cosmetic dermatology. 5th ed. Boca Raton: CRC Press; 2017. p. 473-80.
11. Antonio CR, Antonio JR, Oliveira GB, Alves FT. Polymethylmethacrylate (PMMA) filling
in the lower limbs of a patient with lipodystrophy caused by antiretroviral drugs.
Surg Cosmet Dermatol. 2014;6(4):373-5.
12. Kwiatt ME, Seamon MJ. Fat embolism syndrome. Int J Crit Illn Inj Sci. 2013 Jan;3(1):64-8.
13. Salgado EG, Olvera RM. Síndrome de embolia grasa secundario a infiltración de polimetilmetacrilato
em región glútea. Cir Plast. 2008;18(2):78-80.
14. Jorens PG, Van Marck E, Snoeckx A, Parizel PM. Nonthrombotic pulmonary embolism. Eur
Respir J. 2009 Aug;34(2):452-74.
15. Gupta A, Reilly CS. Fat embolism. Contin Educan Aesthetic Crit Care Pain. 2007 Oct;7(5):148-51.
1. Pontifícia Universidade Católica de Minas Gerais,Betim, MG,Brazil.
2 . Hospital Eduardo de Menezes, Departamento de Infectologia, Belo Horizonte, MG,
Brazil.
Corresponding author: Carina Gabriela Andrade Oliveira, Rua Pintarroxo, 157, Bairro Goiânia, Belo Horizonte, Minas Gerais, MG, Brazil. Zip
Code: 31950-110. E-mail: carina.andradde@gmail.com
Article received: June 29, 2019.
Article accepted: February 29, 2020.
Conflicts of interest: none.